Publications
57
Citations
317
Est. group size
~10
Recurring co-author estimate
Active years
8
Publishing since 2019
Typically publishes in teams of ~12 · 5% small-team papers (≤3 authors) · across 16 venues
- Circulating tumor DNA (ctDNA) as a real-time biomarker in marker-negative germ cell tumors (GCT): A proof-of-concept study.
Journal of Clinical Oncology · 2026
- CONSOLIDATE: A phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA.
Journal of Clinical Oncology · 2026
- Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.
Journal of Clinical Oncology · 2026
- Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP).
Journal of Clinical Oncology · 2026
- Correlation of adverse events (AEs) and clinical outcomes in first-line enfortumab vedotin–pembrolizumab (EVP) treatment for locally advanced or metastatic urothelial cancer (La/mUC).
Journal of Clinical Oncology · 2026
- Phase II study of frontline gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma.
Journal of Clinical Oncology · 2026
- Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
Journal of Clinical Oncology · 2026
- Updated results from a pilot trial of neoadjuvant durvalumb in combination with tremelimuab for cisplatin-ineligible high-risk urothelial carcinoma.
Journal of Clinical Oncology · 2026
- Incidence and risk factors for pneumonitis in patients with urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: A retrospective cohort study.
Journal of Clinical Oncology · 2026
- Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the <scp>UNITE</scp> Study
Cancer Medicine · 2025
- Outcomes of Universal Newborn G6PD Deficiency Screening in a Large Urban Cohort
PEDIATRICS · 2025
- Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.
Journal of Clinical Oncology · 2025
- Integrative clinico-genomic evaluation of the human epidermal growth factor receptor 2 (HER2) in urothelial cancer (UC).
Journal of Clinical Oncology · 2025
- Abstract 1746: FGFR3 inhibition is a highly effective therapy in MTAP-deficient, FGFR3 altered urothelial carcinoma
Cancer Research · 2025
- Targeting the TGFβ signaling pathway to mitigate tumor metastasis in 9p21-loss urothelial bladder cancer.
Journal of Clinical Oncology · 2025
- Journal of Clinical Oncology×32
- The Oncologist×3
- JCO Oncology Practice×2
- Research Square×2
- Canada Watch×2
- Irene Tsung
Medicine · University of Michigan
- Eugene Oh
Medicine · University of Michigan
- Amir Mortazavi
Medicine · The Ohio State University
- Ajjai Alva
Medicine · University of Michigan
- Ahsan Masood Khan
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile